InnovAge (INNV) CLO Nicole Damato Sells $32K of Stock

By TradeTexts Research Desk Oct 26, 2026, 5:01 PM EDT

Key Points

Nicole Damato sold 3,402 shares of InnovAge at a price of $9.51 each, totaling about $32,353.
After the sale, she owns 301,495 shares, reducing her stake by about 1.12%.
InnovAge shares recently traded around $9.27, which is below the company's 50-day moving average of $10.00.

Since the trade, $INNV is down 2.6% to date (from the $9.52 close on Oct 22, 2026).

Get InnovAge Holding Corp. text alerts

We text you when insiders, Congress, analysts or big funds move on $INNV.

By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated InnovAge Holding Corp. alert may contain errors. Disclosures

On October 22, 2026, Nicole Damato, the Chief Legal Officer at InnovAge Holding Corp. (INNV), sold 3,402 shares at a price of $9.51 each, amounting to about $32,353. This transaction was reported in a Form 4 filing with the SEC. Following the sale, Damato holds 301,495 shares, which marks a reduction in her ownership by approximately 1.12%. This sale was planned in advance, indicating it was part of a pre-arranged trading strategy.

INNV InnovAge Holding Corp.

$9.27 +78.61% year to date

Daily close · Oct 26, 2026

Other Institutional Activity in InnovAge

Several other institutional investors have also been active with InnovAge. Federated Hermes, Inc. increased its holdings by 1,899,133 shares, ending with 1,903,713 shares valued at about $17.65 million. Arrowstreet Capital, Limited Partnership added 251,196 shares, totaling 668,742 shares worth approximately $6.20 million. Algert Global, LLC grew its stake by 563,735 shares, bringing its total to 630,520 shares valued at around $5.84 million. Acadian Asset Management LLC raised its holdings by 207,671 shares, now holding 390,850 shares worth about $3.62 million.

InnovAge Holding Corp. Stock Down 2.6%

InnovAge shares closed at $9.52 on October 22, 2026. Recently, the stock has traded around $9.27, which is below its 50-day moving average of $10.00. The stock is currently about 26.7% below its 52-week high of $12.64. This performance may be a concern for investors watching the company's trajectory.

Recent Earnings

InnovAge reported trailing twelve-month revenue of approximately $989.7 million. The company has faced challenges, with a net margin of -0.3% and a return on equity of -0.3%. The next earnings report is set for November 3, 2026.

Insider Buying and Selling at InnovAge Holding Corp.

Recently, other insiders have also sold shares. On October 21, 2026, three major 10% owners sold a total of 4.5 million shares at a price of $9.25 each, totaling about $41.65 million. This indicates significant insider activity leading up to Damato's sale.

Analysts Set New Price Targets

On August 21, 2026, Keybanc upgraded InnovAge to an Overweight rating with a price target of $13.00. They later maintained the Overweight rating on September 9, 2026, raising the price target to $14.00. The current consensus among analysts is a mean price target of $12.00, suggesting potential upside for the stock.

About InnovAge

InnovAge Holding Corp. operates in the healthcare sector, providing a range of medical and ancillary services for seniors through its PACE (Program of All-Inclusive Care for the Elderly) approach. The company is based in Denver, Colorado, and employs about 2,500 people. This insider sale occurs amid significant trading activity from other insiders and institutional investors.

Bottom Line

Investors should keep an eye on upcoming earnings on November 3, 2026, and watch for any further insider trading activity. Nicole Damato's planned sale reflects her ongoing stake in InnovAge, which remains substantial despite the recent reduction.